Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022698 · ClinicalTrials.gov registry record · Phase 2
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
A Phase 2 study of Colorectal Cancer, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 17
- Study locations
NCT00022698: Completed Phase 2 study of Colorectal Cancer, sponsored by Hoffmann-La Roche.
NCT00022698 is a Phase 2 study of Colorectal Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 67 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (96% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022698, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 17
- Study locations
Study Summary
PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
Primary Outcome
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (\>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Irinotecan
Study Locations (17)
District of Columbia
- Lombardi Cancer Center at Georgetown University Medical Center - Washington D.C.
- George Washington University Medical Center - Washington D.C.
New York
- HemOnCare, P.C. - Brooklyn
- Lincoln Medical and Mental Health Center - The Bronx
Pennsylvania
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Washington
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus - Seattle
- Rockwood Clinic P.S. - Spokane
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
California
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
Connecticut
- Eastern Connecticut Hematology and Oncology Associates - Norwich
Florida
- University of Florida Health Science Center - Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2001-05 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
What the finished NCT00022698 record still lists
NCT00022698 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT00022698 lists 17 locations in 13 states (District of Columbia, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00022698 about?
NCT00022698 is a clinical study titled "Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer". PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
What is the current status of trial NCT00022698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2001-05. Estimated completion is 2004-12.
What conditions does trial NCT00022698 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT00022698?
The interventions under investigation include: Capecitabine (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00022698?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022698 being conducted?
This trial has 17 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00022698's enrollment target sits among peer trials
67 249th of 381 higher than 132 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia